Tag Archives: Cellceutix

Clinical Biofilm Studies – An Interesting Evolving Landscape

Posted on by — No Comments ↓

A recent article on “Agents that Prevent Biofilm Formation” captured my interest[1].  The authors reviewed the literature and mentioned many substances which have shown in-vitro efficacy in disrupting biofilm production by the main offenders, i.e., S. aureus, S. epidermidis, P. aeruginosa and K. pneumoniae. These substances come with very diverse Continue reading Clinical Biofilm Studies – An Interesting Evolving Landscape→

Brilacidin – QIDP Drug At a Critical Juncture

Posted on by — 3 Comments ↓

At around this time (July 2015), Cellceutix is expected to hammer out a Phase 3 program for brilacidin, its defensin-mimetic and host-defense protein (HDP) mimic structurally similar to magainin, with FDA. Brilacidin is certainly an interesting novel compound, coming from a new class, with a unique mode of action.  It has Continue reading Brilacidin – QIDP Drug At a Critical Juncture→

QIDP Drugs: Here They Are, All of Them

Posted on by — No Comments ↓

For the latest QIDP listing, please click HERE As of Oct. 9, 2014, there were by my accounting 30 compounds with QIDP designation. Here is the break-down:   31 compounds with QIDP designation 29 antibacterials, 2  antifungals 22 systemically active, 9 for topical administration 13 in Phase 3, 9 in Phase Continue reading QIDP Drugs: Here They Are, All of Them→